The effect of treatment with Campath-1H in patients with autoimmune cytopenias.

The effect of treatment with Campath-1H in patients with autoimmune cytopenias.

We describe 21 patients with severe and life-threatening autoimmune cytopenias resistant to standard immunosuppression who were treated with the monoclonal antibody Campath-1H. Four patients had autoimmune neutropenia, four had autoimmune haemolytic anaemia, four had pure red cell aplasia, one had i...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Willis, F, Marsh, J, Bevan, D, Killick, S, Lucas, G, Griffiths, R, Ouwehand, W, Hale, G, Waldmann, H, Gordon-Smith, E
Natura:	Journal article
Lingua:	English
Pubblicazione:	2001

Documenti analoghi

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
di: Killick, S, et al.
Pubblicazione: (1997)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
di: Lim, S, et al.
Pubblicazione: (1993)

CAMPATH-1H in inflammatory arthritis.
di: Watts, R, et al.
Pubblicazione: (1993)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
di: Lim, S, et al.
Pubblicazione: (1993)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
di: Watts, R, et al.
Pubblicazione: (1992)

CAMPATH: from concept to clinic.
di: Waldmann, H, et al.
Pubblicazione: (2005)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
di: Hale, G, et al.
Pubblicazione: (2002)

Specificity of monoclonal antibody Campath-1.
di: Hale, G, et al.
Pubblicazione: (1988)

Availability of Campath-1 antibodies for bone marrow transplantation.
di: Hale, G, et al.
Pubblicazione: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
di: Hale, G, et al.
Pubblicazione: (1994)

Campath-1H therapy in refractory ocular inflammatory disease.
di: Dick, A, et al.
Pubblicazione: (2000)

The CAMPATH-1 antigen (CDw52).
di: Hale, G, et al.
Pubblicazione: (1990)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
di: Hale, G, et al.
Pubblicazione: (1988)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
di: Isaacs, J, et al.
Pubblicazione: (1996)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
di: Williams, R, et al.
Pubblicazione: (2000)

Rituximab for the treatment of autoimmune cytopenias
di: Sigbjørn Berentsen
Pubblicazione: (2007-12-01)

In vivo 'purging' of residual disease in CLL with Campath-1H.
di: Dyer, M, et al.
Pubblicazione: (1997)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
di: Chakrabarti, S, et al.
Pubblicazione: (2004)

A personal history of the CAMPATH-1H antibody.
di: Waldmann, H
Pubblicazione: (2002)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
di: Hale, G, et al.
Pubblicazione: (1996)

Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H.
di: Buggins, A, et al.
Pubblicazione: (2001)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
di: Waldmann, H, et al.
Pubblicazione: (1987)

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.
di: Isaacs, J, et al.
Pubblicazione: (1995)

Refractory Autoimmune Cytopenias Treated With Venetoclax
di: Max J. Gordon, et al.
Pubblicazione: (2019-06-01)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
di: Novitzky, N, et al.
Pubblicazione: (2004)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
di: Clatworthy, MR, et al.
Pubblicazione: (2009)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
di: Watson, C, et al.
Pubblicazione: (2004)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
di: Xia, M, et al.
Pubblicazione: (1993)

CAMPATH-1 antibodies in stem-cell transplantation.
di: Hale, G, et al.
Pubblicazione: (2001)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
di: Dyer, M, et al.
Pubblicazione: (1989)

Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.
di: Hale, G, et al.
Pubblicazione: (1988)

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.
di: Newman, D, et al.
Pubblicazione: (1995)

Targeted treatment of autoimmune cytopenias in primary immunodeficiencies
di: Lucia Pacillo, et al.
Pubblicazione: (2022-08-01)

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.
di: Calne, R, et al.
Pubblicazione: (1998)

1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
di: James, L, et al.
Pubblicazione: (1999)

Inflammation, demyelination, and axonal degeneration: Three aspects of the pathogenesis of multiple sclerosis revealed by campath-1H treatment
di: Coles, A, et al.
Pubblicazione: (2003)

CAMPATH-IH in multiple sclerosis.
di: Moreau, T, et al.
Pubblicazione: (1996)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
di: Dyer, M, et al.
Pubblicazione: (1989)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
di: Dyer, M, et al.
Pubblicazione: (1990)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
di: Friend, P, et al.
Pubblicazione: (1988)